Current soluble biomarkers in blood and urine for early AKI diagnosis have largely focused on indicators of renal parenchymal damage and sterile inflammation, such as kidney injury molecule-1 (KIM-1) [5,6], neutrophil gelatinase-associated lipocalin (NGAL) [7], liver-type fatty acid-binding protein [8], and interleukin (IL)-18 [9]. The gene discussed is LCN2; the disease is acute kidney injury.